{
    "thread": {
        "uuid": "6417e318e4ed5a3f840a473aec2de2cedb9fe4e7",
        "url": "https://www.defenseworld.net/2024/11/15/praxis-precision-medicines-inc-nasdaqprax-given-average-rating-of-moderate-buy-by-brokerages.html",
        "site_full": "www.defenseworld.net",
        "site": "defenseworld.net",
        "site_section": "https://www.defenseworld.net",
        "site_categories": [
            "media"
        ],
        "section_title": "Defense World",
        "title": "Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of “Moderate Buy” by Brokerages",
        "title_full": "Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of “Moderate Buy” by Brokerages",
        "published": "2024-11-15T14:56:00.000+02:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "main_image": "",
        "performance_score": 0,
        "domain_rank": 31217,
        "domain_rank_updated": "2024-11-11T23:00:00.000+02:00",
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "6417e318e4ed5a3f840a473aec2de2cedb9fe4e7",
    "url": "https://www.defenseworld.net/2024/11/15/praxis-precision-medicines-inc-nasdaqprax-given-average-rating-of-moderate-buy-by-brokerages.html",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Defense World Staff",
    "published": "2024-11-15T14:56:00.000+02:00",
    "title": "Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of “Moderate Buy” by Brokerages",
    "text": "Shares of Praxis Precision Medicines, Inc. ( NASDAQ:PRAX \\u2013 Get Free Report ) have received a consensus rating of \\u201cModerate Buy\\u201d from the nine brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $146.33. A number of equities analysts have recently weighed in on PRAX shares. Needham & Company LLC reiterated a \\u201cbuy\\u201d rating and set a $151.00 target price on shares of Praxis Precision Medicines in a research note on Thursday, November 7th. HC Wainwright reissued a \\u201cbuy\\u201d rating and set a $120.00 target price on shares of Praxis Precision Medicines in a report on Thursday, November 7th. Wedbush upped their price target on shares of Praxis Precision Medicines from $40.00 to $48.00 and gave the company a \\u201cneutral\\u201d rating in a research note on Wednesday, August 14th. Oppenheimer lifted their price objective on shares of Praxis Precision Medicines from $143.00 to $163.00 and gave the stock an \\u201coutperform\\u201d rating in a research note on Thursday, October 31st. Finally, Guggenheim increased their target price on shares of Praxis Precision Medicines from $155.00 to $170.00 and gave the stock a \\u201cbuy\\u201d rating in a research report on Wednesday, August 14th. Check Out Our Latest Research Report on PRAX Shares of PRAX opened at $76.88 on Friday. The firm has a market capitalization of $1.43 billion, a PE ratio of -7.46 and a beta of 2.67. The company\\u2019s 50-day moving average is $66.29 and its 200-day moving average is $54.75. Praxis Precision Medicines has a fifty-two week low of $13.50 and a fifty-two week high of $86.93. Praxis Precision Medicines ( NASDAQ:PRAX \\u2013 Get Free Report ) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($2.75) earnings per share for the quarter, missing the consensus estimate of ($2.01) by ($0.74). Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%. The company had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.53 million. During the same period in the prior year, the company earned ($2.70) earnings per share. Analysts predict that Praxis Precision Medicines will post -10.26 earnings per share for the current fiscal year. Several large investors have recently made changes to their positions in PRAX. Price T Rowe Associates Inc. MD acquired a new stake in Praxis Precision Medicines in the first quarter valued at about $32,707,000. Vanguard Group Inc. boosted its stake in shares of Praxis Precision Medicines by 100.6% in the 1st quarter. Vanguard Group Inc. now owns 744,069 shares of the company\\u2019s stock valued at $45,403,000 after purchasing an additional 373,131 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Praxis Precision Medicines by 523.2% in the 2nd quarter. Renaissance Technologies LLC now owns 75,433 shares of the company\\u2019s stock valued at $3,120,000 after purchasing an additional 63,329 shares in the last quarter. TD Asset Management Inc grew its holdings in shares of Praxis Precision Medicines by 46.6% during the 2nd quarter. TD Asset Management Inc now owns 51,312 shares of the company\\u2019s stock valued at $2,122,000 after purchasing an additional 16,312 shares during the last quarter. Finally, Moody Aldrich Partners LLC increased its position in Praxis Precision Medicines by 29.6% during the 3rd quarter. Moody Aldrich Partners LLC now owns 31,605 shares of the company\\u2019s stock worth $1,819,000 after purchasing an additional 7,224 shares in the last quarter. Institutional investors and hedge funds own 67.84% of the company\\u2019s stock. ( Get Free Report Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
        "Health",
        "Science and Technology",
        "Social Issue"
    ],
    "ai_allow": true,
    "canonical": false,
    "webz_reporter": false,
    "external_links": [
        "https://www.marketbeat.com/stocks/NASDAQ/PRAX/",
        "https://www.marketbeat.com/",
        "https://www.marketbeat.com/arnreports/ReportTickerOptin.aspx?RegistrationCode=TickerHyperlink&Prefix=NASDAQ&Symbol=PRAX",
        "https://www.marketbeat.com/stocks/NASDAQ/PRAX/forecast/",
        "https://www.marketbeat.com/stocks/NASDAQ/PRAX/forecast",
        "https://marketbeat.com/stocks/NASDAQ/PRAX/",
        "https://marketbeat.com/arnreports/ReportTickerOptin.aspx?RegistrationCode=TickerHyperlink&Prefix=NASDAQ&Symbol=PRAX",
        "https://www.marketbeat.com/arnreports/ReportTickerOptin.aspx",
        "https://www.marketbeat.com",
        "https://marketbeat.com/",
        "https://www.marketbeat.com/stocks/NASDAQ/PRAX",
        "https://marketbeat.com/stocks/NASDAQ/PRAX/forecast/"
    ],
    "external_images": [],
    "entities": {
        "persons": [],
        "organizations": [
            {
                "name": "Brokerages Shares of Praxis Precision Medicines, Inc.",
                "sentiment": "neutral"
            },
            {
                "name": "Needham & Company LLC",
                "sentiment": "none"
            }
        ],
        "locations": []
    },
    "syndication": {
        "syndicated": false,
        "syndicate_id": null,
        "first_syndicated": false
    },
    "rating": null,
    "crawled": "2024-11-15T15:32:31.485+02:00",
    "updated": "2024-11-15T15:32:31.485+02:00"
}